Great. Thank you, Johan. Uh, we can dive a little bit more into some of the financials. So, if I start with the group overview here on page six.
Uh, what you see is very much in line with what Johan described. Solid revenue and EBITDA growth and a slightly stronger margin coming through in Q2.
So, the net sales for the group in Q2 were up by 9%. With that headwind included, which Johan mentioned, the growth was driven by strong performances in West and Central and a slightly slower performance in Region North. I'm going to come back to the regions individually in a second, just to put a little bit more color around that.
But net-net, delivering an EBITDA growth up 12% in the quarter, again, with the FX headwind pushing us back a little bit by 3%.
Within that, the EBITDA margin improved marginally in the quarter as well, which is good to see. The new M&A is coming in, enriching the margin and enhancing ongoing operational and synergy efforts within the existing operations. Worth noting, though, is that Q2 also tends to be a seasonally strong quarter for margin.
If I look over to the right hand side of this picture, just to quickly summarize.
H1.
As a whole, we see organic growth up 6% on EBITDA.
We see acquired growth delivering 10%, with the FX headwind we've mentioned, but a total adjusted EBITDA growth for H1 of 14%, which is very much a good solid start to the year. If I dive a little bit now into the regions to try and give you a bit more detail, starting with Business Area North.
Uh, I think the first and most important thing to say is that the underlying core operations in North, the day-to-day activity servicing the regions, the municipalities, all of those healthcare settings are performing extremely, extremely solidly, extremely well across all of the companies and all of the countries in Region North.
We do, however, see an EBITDA decline in the quarter. Um, and that's due to the irregular project-based sales activities that we talked a little bit about in Q1 and is continuing to challenge the figures a bit in Q2, particularly in the defense and preparedness area where we had very strong performance in the same period last year.
We have also made good progress with the development of our new larger distribution center in Gothenburg.
Uh, that has had its first large CAPEX expenditures, which come into the cash flow, and I'll talk a little bit more about them later. But overall, if you look at H1 as a whole on the right-hand side here, adjusted EBITDA growth is actually down 7%, with net sales down 2% in the first half of the year for those reasons mentioned. And those reasons that I talked about are related to the irregular project-based activities.
If I turn to Region West, we see a very nice development, strong organic growth, and improved margins in Region West.
A large part of that organic growth is driven by increased patient numbers.
We also mentioned this earlier in the year as a result of some larger customer databases that we took over during the second half of 2023. And those increased patient numbers are still flowing through nicely into the figures.
We also get a good uplift from the acquisitions that we've done in the region. Uh, the large HSL acquisition we did in February this year, is also fitting nicely into the numbers and performing well in line with expectations. The EBITDA margin is also strengthened a little in the region.
Uh, again, a mix of different activities contributing to that, both the organic synergy benefits we see from increased cooperation between our companies, especially within the home care hub that we're seeing developing very nicely in Region West, but also activities across the group with looking at product mix and how we enrich that across our companies.
So H1 as a whole, 31% adjusted EBITDA growth, sales growth of 17% in the same period, and then the third of our region's business area, central.
Also, we have some good growth figures to present here, primarily driven by the high pace of acquisition activity that we see in Central.
So sales are up 25% in the quarter. EBITDA is up 61% in the quarter.
And as I say, M&A is a big part of that driver. We also see improved EBITDA margins moving up towards the margins that we observe in the other regions. And that comes again from a variety of activities.
Um, the new M&A is coming in, enriching the mix. Um, but we've also had quite a focus on our organic business and the margin within our organic business in the Central region as well.
And that's meant that we have been prepared to sacrifice a little bit of revenue growth to get margins up in the region.
So overall, H1 EBITDA growth shows an adjusted EBITDA growth of 68% and a net sales growth of 31%.
If I turn briefly now here on page ten to the R/RK (EBITA/NWC) metric.
This is, as we've talked a lot about in the past, our key internal performance metric, making sure that we're focused on efficient working capital utilization. And again, we're pleased to see that it remains well above our Asker target of 15%.
And it's also, of course, an area that we continue to put a lot of effort into with our new companies, our M&A coming into the group. A word or two on the cash flow as well.
Um, we see slightly lower operating cash flow compared to the high levels observed in Q2 2024. Um, and actually in 2024, the comparable period, we did have relatively low levels of working capital and very high levels of cash inflow.
Again, relating in large part to these project-based sales in North that I've talked about before, we got paid for a lot of the activity that we'd done all the way through H1, and a lot of that money came in during Q2 2024. So the slightly lower level that you see in Q2 2025 is more about the comparables than anything to do with Q2 2025 on a standalone basis. I mentioned earlier, we have had the first of the larger investments in the Gothenburg distribution center.
Um, we also paid to take over some distribution rights, and there are some interesting new products coming into the portfolio within the Baltic region that we look forward to delivering strongly in the future. So that was the paid acquisition.
Um, the other large chunk of that, -160 million, comes from the earnouts, the contingent considerations that we've paid for previous acquisitions that we've done. And then you see the financing is a large positive 730 million that you see there. That is actually us drawing down cash from our revolving credit facility to pay for the acquisitions that came in early July, primarily Scan Modul. So actually, that money has already been spent in the early weeks of July to complete the acquisition of Scan Modul.
And then a final page from me before I hand it back to Johan.
The leverage levels are remaining at a relatively low level of 1.8x; since the comparable period, the net debt has obviously risen a little, but we've done more than that through that period. But we brought in, uh, capital through the equity issue at the time of the IPO.
But at the same time, obviously, the group has grown strongly and the EBITDA has risen through that period.
So the net effect of those two, uh, is that the net debt to EBITDA ratio is at 1.8 as of the end of June, and as Johan mentioned earlier, the attractive pipeline is good because we have a little bit of headroom now within the leverage to, uh, take advantage of that attractive pipeline. All right. I think I'll leave it there, Joanna, and pass it back to you.